Skip to main content
. 2018 Aug 3;104(1):82–92. doi: 10.3324/haematol.2018.191213

Figure 5.

Figure 5.

Expression of the miR-17-92 cluster and its target FRZB correlates with MYB levels in Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) cells. (A) MiR-17-92 expression levels evaluated by stem-loop qRT-PCR in primary leukemia cells (Patient 1: p210BCR/ABL chronic myeloid leukemia (CML)-myeloid blast crisis) compared to normal CD34+ cells from a healthy subject [Control (Ctrl) CD34+] and Patient 2 (p190BCR/ABL ALL) compared to normal peripheral blood mononuclear (PBMC) cells (Ctrl/PB). Samples were normalized for RNU44 small-nucleolar RNA expression using the comparative Ct method. Data are the average of three experiments; error bars indicate Standard Deviation (SD). (B) mRNA quantification of MYB and FRZB, by SYBR Green-based qRT-PCR, in Patient 1 (p210BCR/ABL CML-myeloid blast crisis) and Patient 2 (p190BCR-ABL ALL) compared to normal CD34+ cells and PBMC cells from healthy donors (Ctrl/CD34+ and Ctrl/PB), respectively. Values are reported as 2-ΔCt normalizing to GAPDH gene expression. (C) mRNA expression by microarray of MYB or FRZB in normal B cells or Ph+ ALL cells. (Values represent the sum of all probes signals for each gene and are derived from dataset GSE13159).